BioMosaics' kidney disease test certified in over 40 countries; US commercialization to start Q3 driving growth
NQ Score
0/100
N1 Content Completeness
9
AI Summary (NQ-processed)
BioMosaics' kidney disease biomarker test has obtained certification in over 40 countries. US commercialization via LDT will begin in Q3, making this year the start of revenue growth.